康臣药业(01681.HK)中期纯利增加约13.9%至2.49亿元中期息每股0.1港元
格隆汇8月21日丨康臣药业(01681.HK)公布,截至2019年6月30日止六个月,实现收入人民币9.41亿元(单位下同),同比增加约8.3%;毛利6.87亿元,同比增长5.38%;公司权益股东应占溢利2.49亿元,同比增加约13.9%;每股基本盈利0.2929元;拟派中期股息每股0.1港元。
公告称,按产品系列分类,肾科系列产品销售较去年录得增长约16.2%,其中尿毒清颗粒仍然是集团的皇牌产品,维持在肾病口服现代中成药市场的领先地位。
医用成像对比剂销售虽然较去年增加11.7%,仍然稳占国内磁共振成像对比剂市场的前列;骨伤系列产品销售下降约15.7%;皮肤系列产品销售略微下降约1.2%。
此外,妇幼系列产品销售增长约14.2%;及其他药物销售增长约2.2%。整体销售收入的增加主要是由于集团持续开发产品市场以调整发展在全国各地的销售网路所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.